Abstract: The present invention provides a method of assessing type 2 diabetes susceptibility and/or predicting treatment responsiveness in a human subject, the method comprising determining the identity of at least one allele at each of three or more positions of single nucleotide polymorphism (SNP) selected from the group consisting of: SLC16A11-rs75493593; HNF1A-rs483353044; TCF7L2-rs7903146; CDKN2A/B-rs10811661; CDKAL1-rs7756992; SLC30A8-rs3802177; IGF2BP2-rs4402960; FTO-rs9936385; PPARG-rs1801282; HHEX/IDE-rs1111875; ADCYS-rs11717195; JAZF1-rs849135; WSF1-rs4458523; INS-IGF2-rs149483638; KCNQ1-rs2237897; and KCNJ11-rs5219, and/or an SNP in linkage disequilibrium with any one of said SNPs at r2>0.8. Also provided are a genotyping tool and a type 2 diabetes risk assessment system for use in the method of the invention.
Type:
Grant
Filed:
April 28, 2020
Date of Patent:
February 14, 2023
Assignee:
Patia Biopharma, S.A. De C.V.
Inventors:
Laureano Simón Buela, Mirella G. Zulueta
Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
August 10, 2021
Assignee:
Patia Biopharma S.A. de C.V.
Inventors:
Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
Type:
Application
Filed:
December 16, 2016
Publication date:
September 10, 2020
Applicant:
Patia Biopharma, S.A. de C.V.
Inventors:
Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié